Predicted effect-site concentrations of remimazolam for i-gel insertion: a prospective randomized controlled study.

Abstract

This study is the first to report 50% and 95% effect-site concentrations (EC50 and EC95, respectively) of the new short-acting benzodiazepine, remimazolam, for the successful insertion of i-gels with co-administration of fentanyl. Thirty patients (38 ± 5 years old, male/female = 4/26) were randomly assigned into five groups to receive one of five different remimazolam doses (0.1, 0.15, 0.2, 0.25, and 0.3mg/kg bolus followed by infusion of 1, 1.5, 2, 2.5, and 3mg/kg/h, respectively, for 10min), which were designed to maintain a constant effect-site concentration of remimazolam at the time of i-gel insertion. At 6min after the start of remimazolam infusion, all patients received 2µg/kg fentanyl. i-gel insertion was attempted at 10min and the success or failure of insertion were assessed by the patient response. Probit analysis was used to estimate the EC50 and EC95 values of remimazolam with 95% confidence intervals (CIs). In the five remimazolam dose groups, two, two, four, five, and six of the six patients in each group had an i-gel successfully inserted. Two patients in the lowest remimazolam dose group were conscious at the time of i-gel insertion and were counted as failures. The EC50 and EC95 values of remimazolam were 0.88 (95% CI, 0.65-1.11) and 1.57 (95% CI, 1.09-2.05) µg/ml, respectively. An effect-site concentration of ≥ 1.57µg/ml was needed to insert an i-gel using remimazolam anesthesia, even with 2µg/kg fentanyl. Trial registration: The study was registered in Japan Registry of Clinical Trials on 19 April 2021, Code jRCTs041210009.